Paloma Wang

Ms. Wang’s experience prior to joining Skadden included advising:

• WuXi Biologics (Cayman) Inc. and G&C VII Limited in their respective capacity as the issuer and controlling shareholder on the approximately US$600 million placing of new shares and existing shares;
• Future Land Development Holdings Limited on its approximately US$200 million top-up share placing and issuance of approximately US$300 million convertible notes;
• WuXi Biologics Holdings Limited on the sale of its existing shares of WuXi Biologics (Cayman) Inc. for a consideration of approximately US$650 million;
• the underwriters on the approximately US$510 million global offering and initial public offering of WuXi Biologics (Cayman) Inc. on the Hong Kong Stock Exchange;
• Sinco Pharmaceuticals Holdings Limited on its global offering and initial public offering on the Hong Kong Stock Exchange;
• the underwriters on the approximately US$1.15 billion global offering and initial public offering of Dali Foods Group Company Limited on the Hong Kong Stock Exchange;
• CGN Power Co. Ltd. , China’s largest nuclear power producer, on its US$3.2 billion global offering and initial public offering on the Hong Kong Stock Exchange;
• the underwriters on the approximately US$203 million global offering and initial public offering of Guorui Properties Limited on the Hong Kong Stock Exchange;
• Danone Asia Pte. Ltd. on its sale of Dumex Baby Food Co., Ltd. to Yashili International Holdings Limited and investment in China Mengniu Dairy Company Limited;
• the underwriters on the approximately US$500 million global offering and initial public offering of H shares of China Machinery Engineering Corporation on the Hong Kong Stock Exchange;
• Future Land Development Holdings Limited on its approximately US$265 million global offering and initial public offering on the Hong Kong Stock Exchange;
• Midas Holdings Limited , a Singapore-incorporated company, on its approximately US$150 million secondary listing on the Hong Kong Stock Exchange;
• the underwriters on the approximately HK$1.3 billion global offering and initial public offering of Besunyen Holdings Company Limited on the Hong Kong Stock Exchange; and
• the sponsor on the listing by way of introduction of China Animal Healthcare Ltd. on the Hong Kong Stock Exchange.

Ms. Wang joined Skadden in 2018 and prior to that worked in the Hong Kong office of another highly regarded global law firm as a partner in its capital markets practice. She is noted for her “distinguished leadership” by Asia Pacific Legal 500 2017. Ms. Wang speaks fluent English, Mandarin and Cantonese.